LBA32 A Randomized, Phase II, Dose Optimization of Gotistobart, a Ph-Sensitive Anti-Ctla-4, in Combination with Standard Dose Pembrolizumab in Platinum-Resistant Recurrent Ovarian Cancer: Safety, Efficacy and Dose Optimization (PRESERVE-004/GOG-3081)

J.N. Barlin, P.C. Lim, J. Thomes Pepin, E.E. Hopp,N.G. Cloven, C. Lee, H.D. Eshed,D. Black, H.M. Cottrill, L. Hand, D.M. O'Malley,L.T. Chuang,L. Willmott,M. Chisamore, S. Shpyro, J. Durbin, P. Zheng, Y. Liu, B.J. Monk

Annals of Oncology（2024）

Cited 0|Views4

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined